Last Updated: November 16, 2026

Investigational Drug Information for PF-04457845

« Back to Dashboard


What is the drug development status for PF-04457845?

PF-04457845 is an investigational drug.

There have been 10 clinical trials for PF-04457845. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Marijuana Abuse, Stress Disorders, Traumatic, and Chronic Pain. The leading clinical trial sponsors are Pfizer, Yale University, and National Institute on Drug Abuse (NIDA).

Recent Clinical Trials for PF-04457845
TitleSponsorPhase
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)Columbia UniversityPhase 2
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)Johns Hopkins UniversityPhase 2
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)Medical University of South CarolinaPhase 2

See all PF-04457845 clinical trials

Clinical Trial Summary for PF-04457845

Top disease conditions for PF-04457845
Top clinical trial sponsors for PF-04457845

See all PF-04457845 clinical trials

PF-04457845 Development Update and Market Projection

Last updated: September 5, 2026

PF-04457845 is a Pfizer-developed, selective fatty acid amide hydrolase (FAAH) inhibitor that reached human clinical testing but did not advance to approval or commercial launch. The program has no identifiable current revenue base, no FDA-approved indication, and no credible standalone market forecast. Its commercial value is therefore tied to licensing, research-platform use, or revival of the FAAH mechanism rather than direct product sales.

What is PF-04457845?

PF-04457845 is an orally administered FAAH inhibitor designed to increase endogenous cannabinoid signaling by preventing the breakdown of anandamide and related fatty acid amides. The mechanism was investigated for pain and central nervous system disorders.

Attribute PF-04457845
Developer Pfizer
Drug class Selective FAAH inhibitor
Mechanism Inhibits fatty acid amide hydrolase and increases endocannabinoid levels
Route Oral
Development stage reached Phase 1 and Phase 2 clinical testing
Approved indication None
FDA approval None identified
Commercial launch None identified
Current branded product None
Current market revenue None identified
Principal historical use areas Osteoarthritis pain and other CNS-related indications

FAAH inhibitors differ from direct cannabinoid receptor agonists because they are intended to amplify endogenous signaling rather than produce broad CB1 receptor activation. The approach was expected to preserve analgesic or anxiolytic effects while reducing intoxication, abuse, and psychotropic effects associated with exogenous cannabinoids.

What was the development history of PF-04457845?

PF-04457845 completed early clinical studies demonstrating target engagement and substantial increases in circulating endocannabinoid-related biomarkers. Pfizer then evaluated the compound in patients, including studies involving osteoarthritis pain.

Early pharmacology supported the biological mechanism. Clinical development did not establish a commercially viable efficacy profile. Publicly available trial records and scientific publications do not show progression into late-stage registration studies, a New Drug Application, or a marketing authorization.

Key development milestones

Period Development event Commercial implication
Preclinical period Pfizer developed PF-04457845 as a potent and selective FAAH inhibitor Established a proprietary endocannabinoid mechanism
Early clinical development Phase 1 studies evaluated safety, pharmacokinetics, pharmacodynamics, and biomarker effects Demonstrated human target engagement
Mid-stage development Phase 2 studies evaluated pain-related indications, including osteoarthritis Clinical efficacy was not sufficient for late-stage advancement
Subsequent period No public Phase 3 program, regulatory filing, or launch emerged Program did not become a commercial medicine
Current status No active marketed product or publicly documented late-stage development program Direct market opportunity is effectively inactive

The clinical record is materially different from the 2016 BIA 10-2474 incident in France. BIA 10-2474 was a separate FAAH inhibitor developed by Bial. The BIA program produced severe adverse events, including death, and affected the broader perception of FAAH drug development. PF-04457845 was not the same molecule and should not be treated as the cause of that incident.

What clinical results affected PF-04457845 development?

The central development problem was the separation between pharmacodynamic activity and clinical benefit. PF-04457845 produced evidence that FAAH was inhibited in humans, but biomarker changes did not translate into a sufficiently differentiated therapeutic effect in the publicly documented patient studies.

In osteoarthritis, the compound was evaluated against pain-related endpoints. The available clinical literature did not establish a benefit strong enough to support a broad analgesic development program. The absence of a Phase 3 trial and regulatory submission indicates that Pfizer did not pursue commercialization after mid-stage testing.

The development risk profile had four elements:

  1. Target engagement was measurable, but clinical efficacy was limited.
  2. Pain indications have high placebo response and strong competition from established therapies.
  3. FAAH inhibition required a favorable therapeutic window across central and peripheral effects.
  4. The program lacked a clear commercial position against NSAIDs, opioids, anticonvulsants, antidepressants, and emerging non-opioid analgesics.

Is PF-04457845 FDA approved or listed in the Orange Book?

No. PF-04457845 has no FDA approval, no approved label, and no Orange Book listing identified.

Because the compound never reached approval:

  • There is no FDA regulatory exclusivity period.
  • There is no New Chemical Entity exclusivity period.
  • There is no orphan-drug exclusivity.
  • There are no Orange Book patent listings.
  • There is no Abbreviated New Drug Application pathway tied to the compound.
  • There is no standard Paragraph IV litigation framework for PF-04457845.

This distinction is important. Pfizer may have filed patents covering the compound, analogs, formulations, or methods of treatment, but patent rights do not create an approved-product market when the underlying medicine has not reached commercialization.

What patents protect PF-04457845?

PF-04457845 was developed within Pfizer's broader patent portfolio for FAAH inhibitors and related endocannabinoid-modulating compounds. Public compound databases and patent literature identify Pfizer-associated filings covering chemical matter and therapeutic use of FAAH inhibitors, but the available public record does not support a definitive, current claim chart for every PF-04457845-specific patent family.

The likely protection categories were:

Protection category Relevance to PF-04457845
Composition of matter Primary protection for the molecule and structurally related compounds
Pharmaceutical compositions Coverage for dosage forms and excipients
Methods of treatment Potential claims for pain, inflammation, CNS disorders, or related conditions
Salt and crystalline forms Possible lifecycle protection if specific forms were developed
Manufacturing methods Potential protection for synthesis and intermediates
Biomarker or dosing methods Possible claims associated with FAAH inhibition and patient selection

The practical value of historical patents is limited by expiration timing, prosecution outcomes, claim scope, terminal disclaimers, and whether the molecule was ever commercialized. A patent estate can protect a development program without creating a viable market monopoly.

How strong is the PF-04457845 patent estate?

The patent estate was likely strongest during the preclinical and early clinical periods, when composition-of-matter claims could have provided the principal barrier to direct copying. Its present commercial strength is low for three reasons:

  • No approved product generates protected sales.
  • The program did not advance to a regulatory filing.
  • FAAH competitors can pursue distinct chemical matter or alternative mechanisms.

Any remaining patent rights would have value mainly for freedom-to-operate analysis, repurposing, or licensing of chemical and pharmacological know-how. A definitive expiration analysis cannot be stated from the compound code alone because multiple patent families may cover different aspects of the program.

When did PF-04457845 lose exclusivity?

PF-04457845 did not lose FDA market exclusivity because it never obtained FDA approval. The relevant commercial event was development discontinuation, not generic erosion.

Patent exclusivity may have expired or may remain in isolated jurisdictions depending on the specific patent family. Composition-of-matter patents for a discovery program initiated in the 2000s would generally face expiration in the 2020s, subject to filing dates, patent-term adjustments, patent-term extensions, and jurisdictional prosecution history. That does not create a generic-launch event because no reference listed drug exists.

Were there Paragraph IV challenges or patent litigation?

No public Paragraph IV challenge or ANDA litigation directed specifically at PF-04457845 has been identified. That outcome is expected for a development-stage compound without an approved reference product.

No major publicly reported patent settlement agreement involving PF-04457845 has emerged. There is also no established record of commercial generic manufacturers preparing an ANDA for the compound.

The absence of litigation does not demonstrate weak patent drafting. It reflects the lack of an approved product with meaningful sales exposure.

What is the biosimilar risk for PF-04457845?

Biosimilar risk is not applicable. PF-04457845 is a small molecule, not a biologic. If the compound were revived, competition would arise through conventional generic-drug pathways rather than biosimilar applications.

A revived product would face two distinct risks:

  • Patent and regulatory barriers during the remaining exclusivity period.
  • Rapid generic competition after loss of composition and formulation protection.

What formulations are protected by PF-04457845 patents?

Publicly available development information does not establish a commercially important formulation platform for PF-04457845. The compound was studied as an oral small molecule, so potential formulation claims could include tablets, capsules, solid dispersions, salts, polymorphs, and methods for improving absorption or stability.

No marketed extended-release, transdermal, injectable, or abuse-deterrent formulation has been identified. No formulation franchise comparable to a differentiated delivery product developed around a commercial drug exists.

Which companies are challenging PF-04457845?

No company has been identified as actively challenging PF-04457845 through an ANDA, Paragraph IV certification, biosimilar application, or public patent litigation.

The competitive threat came from mechanism substitutes and competing pain medicines rather than direct generic challengers. Relevant competitive categories included:

Competitive category Examples of commercial or clinical alternatives Risk to PF-04457845
NSAIDs Celecoxib, naproxen, ibuprofen Low-cost, established pain treatment
Opioids Multiple generic opioid products Strong analgesia but safety and abuse limitations
Neuropathic pain drugs Duloxetine, pregabalin, gabapentin Compete for chronic pain prescribing
Cannabinoid medicines Dronabinol and other cannabinoid-related products Compete for endocannabinoid-related positioning
Other FAAH inhibitors Compounds from Bial, Vernalis and other developers Mechanistic competition and class-level safety concerns
Novel non-opioid analgesics Later-stage sodium-channel and neuroimmune programs Potentially stronger efficacy differentiation

What is the market projection for PF-04457845?

The base-case market projection is zero direct product revenue because PF-04457845 has not been approved or commercialized. A conventional peak-sales forecast would therefore be misleading.

Direct commercial forecast

Scenario Probability characterization Revenue outlook
Existing program remains inactive Base case $0 product revenue
Pfizer or a licensee revives the molecule Low-probability scenario Dependent on new Phase 2 efficacy and safety data
Molecule is repurposed into a new indication Low-probability scenario Potential value only after renewed clinical development
FAAH mechanism succeeds through another molecule Does not create PF-04457845 revenue Benefits competing assets, not this compound

A revived PF-04457845 program would require new investment in formulation, toxicology review, clinical dose selection, patient selection, and controlled efficacy studies. The prior clinical record would raise the evidentiary threshold for investors and potential licensees.

Commercial ceiling if development resumed

The addressable market would depend on the indication. Chronic pain is large, but the product would need to demonstrate clear advantages over generic NSAIDs, duloxetine, pregabalin, and opioids. A niche indication such as treatment-resistant neuropathic pain could support premium pricing, but that would require proof of clinically meaningful efficacy and a favorable abuse and safety profile.

The molecule would not automatically command an endocannabinoid premium. Payers would likely evaluate it against inexpensive generic alternatives unless it showed:

  • Superior pain reduction;
  • Lower gastrointestinal, renal, respiratory, or abuse risk;
  • Durable benefit in chronic use;
  • A clear responder population;
  • Convenient oral dosing; and
  • Evidence supporting reduced healthcare utilization.

How does PF-04457845 compare with other FAAH inhibitors?

PF-04457845 was among the better-characterized FAAH inhibitors in human studies, but its development trajectory was not commercially successful.

Compound Developer Development outcome Market status
PF-04457845 Pfizer Early and mid-stage clinical testing; no approval No market
BIA 10-2474 Bial Development terminated after severe French trial events No market
URB597 Academic and preclinical developers Primarily research-stage compound No market
Other FAAH inhibitors Multiple companies Mixed early clinical and preclinical outcomes No approved broad FAAH inhibitor franchise identified

The class has faced a difficult translation problem: strong preclinical rationale and measurable human pharmacology have not consistently produced differentiated clinical outcomes.

What manufacturing and intellectual-property barriers would affect revival?

A revival would face fewer manufacturing barriers than a biologic because PF-04457845 is a small molecule. Standard synthetic chemistry, impurity control, solid-state characterization, and oral dosage-form manufacturing would be feasible for an experienced pharmaceutical manufacturer.

The principal barriers would be:

  • Reconstructing or validating the original manufacturing process;
  • Confirming impurity and metabolite specifications;
  • Establishing current Good Manufacturing Practice production;
  • Reassessing long-term toxicity and central nervous system effects;
  • Determining whether critical patents remain enforceable;
  • Avoiding third-party claims on alternative FAAH inhibitor chemistry; and
  • Repeating clinical work under current regulatory expectations.

The main obstacle is clinical and commercial validation, not large-scale manufacturing capacity.

What licensing deals involve PF-04457845?

No major public licensing transaction centered specifically on PF-04457845 has been identified. Pfizer appears to have retained control during its principal development period, and no marketed successor product has been publicly linked to the molecule.

A future transaction would likely be structured as an asset sale, regional license, or option agreement rather than a conventional late-stage licensing deal. Valuation would be discounted heavily because the asset lacks current clinical momentum, regulatory exclusivity, and revenue.

What generic launch risks exist?

There is no near-term generic launch risk because there is no approved PF-04457845 reference product. If the molecule were revived and approved, generic entry would depend on:

  1. Remaining composition-of-matter patent term;
  2. Formulation and method-of-use claims;
  3. Regulatory exclusivity;
  4. Whether the label supported a carve-out for patented indications;
  5. The commercial size of the indication; and
  6. The number of alternative FAAH inhibitors or pain treatments available.

A future generic manufacturer would probably face limited incentive to enter unless the drug achieved substantial sales or became a standard therapy.

Key Takeaways

  • PF-04457845 is a Pfizer FAAH inhibitor that reached Phase 1 and Phase 2 testing.
  • The molecule was not approved by the FDA and has no Orange Book listing.
  • No commercial launch, product revenue, Paragraph IV challenge, biosimilar risk, or major patent litigation has been identified.
  • Clinical development did not progress to Phase 3 or regulatory submission.
  • The central failure was inadequate translation from FAAH target engagement to differentiated clinical efficacy.
  • The current direct market forecast is effectively zero.
  • Any residual value lies in historical patents, clinical data, mechanistic know-how, or a potential licensing and repurposing transaction.
  • A revival would require new clinical validation and would face strong competition from established pain treatments.

FAQs

Is PF-04457845 still in clinical development?

No active late-stage clinical development program has been publicly documented. The compound did not reach Phase 3 or regulatory filing.

Did PF-04457845 cause the BIA 10-2474 deaths?

No. PF-04457845 and BIA 10-2474 were different FAAH inhibitors developed by different companies.

Can a generic company launch PF-04457845?

There is no approved reference product for an ANDA-based launch. A generic company cannot create a conventional generic market without an approved product and commercial label.

Could PF-04457845 be repurposed for anxiety or addiction?

The mechanism could support research in pain, anxiety, addiction, or other CNS indications, but no current clinical program has established a viable repurposing pathway for PF-04457845.

Does PF-04457845 have biosimilar competition?

No. It is a small molecule, so any future competition would involve generic-drug regulation rather than biosimilar approval.

References

  1. ClinicalTrials.gov. (n.d.). Studies involving PF-04457845. U.S. National Library of Medicine.
  2. Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012). An efficient randomised, placebo-controlled clinical trial of a FAAH inhibitor in osteoarthritis pain. Pain.
  3. Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chemical Reviews, 108(5), 1687-1707.
  4. European Medicines Agency. (n.d.). Public information on fatty acid amide hydrolase inhibitor development and clinical safety assessments.
  5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.